Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate

Journal of Visualized Experiments

Volumn , Issue 79, 2013, Pages

  Taymans, Jean Marc ^a   Gao, Fangye ^a   Baekelandt, Veerle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

32P orthophosphate; Autoradiography; Biochemistry; Bioengineering (general); Biology (general); Cellular Biology; Immunoprecipitation; Issue 79; LRRK1; LRRK2; Metabolic labeling

Indexed keywords

LRRK1 PROTEIN, HUMAN; LRRK2 PROTEIN, HUMAN; PHOSPHATE; PHOSPHORUS; PROTEIN SERINE THREONINE KINASE;

ARTICLE; AUTORADIOGRAPHY; CELL STRAIN HEK293; CHEMISTRY; HUMAN; IMMUNOPRECIPITATION; ISOLATION AND PURIFICATION; ISOTOPE LABELING; METABOLISM; METHODOLOGY; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; HEK293 CELL LINE; PROCEDURES;

AUTORADIOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; ISOTOPE LABELING; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84886832202     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/50523     Document Type: Article

References (23)

1. Hanafusa, H., et al. Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Commun. 2, 158 (2011).
2. Titz, B., et al. The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene. 29, 5895-5910 (2010).
3. Cookson, M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 11, 791-797 (2010).
4. Taymans, J.M. & Cookson, M. Mechanisms of dominant parkinsonism; the toxic triangle of LRRK2, alpha-synuclein and tau. Bioessays. 32, 227-235 (2010).
5. Lewis, P.A. The function of ROCO proteins in health and disease. Biol Cell. 101, 183-191 (2009).
6. Marin, I., van Egmond, W.N. & van Haastert, P.J. The Roco protein family: a functional perspective. FASEB J. 22, 3103-3110 (2008).
7. Marin, I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol.Biol.Evol. 23, 2423-2433 (2006).
8. Marin, I. Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol. 67, 41-50 (2008).
9. Lobbestael, E., Baekelandt, V. & Taymans, J.M. Phosphorylation of LRRK2: from kinase to substrate. Biochem Soc Trans. 40, 1102-1110 (2012).
10. Gloeckner, C.J., et al. Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2. J Proteome Res. 9, 1738-1745 (2010).
11. Nichols, R.J., et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J. 430, 393-404 (2010).
12. Greggio, E., et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J.Neurochem. 102, 93-102 (2007).
13. Taymans, J.M., et al. LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding. PLoS One. 6, e23207 (2011).
14. Daniëls, V., et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem. 116, 304-315 (2011).
15. Civiero, L., et al. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One. 7, e43472 (2012).
16. Taymans, J.M., Van den Haute, C. & Baekelandt, V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J.Neurochem. 98, 951-961 (2006).
17. Lewis, P.A. Assaying the kinase activity of LRRK2 in vitro. J Vis Exp (2012).
18. Lobbestael, E., et al. Immunohistochemical detection of transgene expression in the brain using small epitope tags. BMC Biotechnol. 10, 16 (2010).
19. Davies, P., et al. Comprehensive Characterization and Optimization of Leucine Rich Repeat Kinase 2 (LRRK2) Monoclonal Antibodies. Biochem J. (2013).
20. West, A.B., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum.Mol.Genet. 16, 223-232 (2007).
21. Sheng, Z., et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 4, 164ra161 (2012).
22. Li, X., et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One. 6, e17153 (2011).
23. Dzamko, N., et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 430, 405-413 (2010).